Paper Details

  1. Home
  2. Paper Details

[Initial results of hybrid chemotherapy of Hodgkin's disease using COPP/VBA].

Author: FleischmannT, MolnárZ, SchneiderT, SzántóI

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A hybrid COPP/ABV regimen showed good response rates in patients with Hodgkin's disease, with complete remission in 8 patients and partial remission in 9. Relapse rates were higher in partial responders. The treatment was well-tolerated with no serious side effects or treatment-related deaths.
Paper Details　
Original Abstract of the Article :
19 patients with advanced, previously untreated Hodgkin's disease were treated with COPP/ABV (cyclophosphamide, vincristine, procarbasine, prednisolone, adriamycin, bleomycine, vinblastine) hybrid regimen. Complete response was achieved in 8 patients, partial response in 9 patients and primary treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1383907

データ提供：米国国立医学図書館（NLM）

COPP/ABV: A Hybrid Chemotherapy Regimen for Hodgkin's Disease

The field of cancer treatment is a vast desert, constantly evolving with new therapies and approaches. This study, published in the European Journal of Cancer, explores the efficacy of a hybrid chemotherapy regimen, COPP/ABV, for treating advanced Hodgkin's disease. The researchers evaluated the response rate and side effects of this regimen in a group of previously untreated patients. This research provides insights into the potential of this hybrid regimen for treating advanced Hodgkin's disease, a potentially life-threatening cancer.

COPP/ABV: A Promising Treatment Option for Hodgkin's Disease

The study reports a significant response rate to the COPP/ABV regimen, with complete or partial responses observed in 17 of the 19 patients. The regimen was well-tolerated, with no serious side effects or treatment-related deaths. This is like finding a new oasis in the desert of cancer treatment, offering a potentially effective and safe option for patients with advanced Hodgkin's disease.

Hope for Patients with Hodgkin's Disease: A New Approach to Treatment

This study offers hope for patients with advanced Hodgkin's disease. The COPP/ABV regimen shows promise as a potentially effective and safe treatment option, offering a new path towards recovery. This research is a reminder that the desert of cancer research is constantly evolving, and with persistent exploration, we can find new oases of hope and healing.

Dr. Camel's Conclusion

This study highlights the importance of continued research and development in cancer treatment. The COPP/ABV regimen is a testament to the ongoing pursuit of new therapies and approaches to fight this devastating disease. We must continue to explore the vast desert of cancer research, seeking new oases of knowledge and innovation that can improve the lives of patients and lead to new cures.

Date :
  1. Date Completed 1992-11-25
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

1383907

DOI: Digital Object Identifier

1383907

Related Literature

Article Analysis
・Side Effects of procarbazine
SNS
PICO Info
in preparation
Languages

Hungarian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.